A 1-year per-patient cost of therapy administration analysis of mosunetuzumab and tisagenlecleucel in relapsed or refractory follicular lymphoma patients receiving two or more lines of systemic therapy
Objective: A per-patient cost of therapy administration model was developed to estimate the cost of mosunetuzumab vs. tisagenlecleucel in patients with relapsing or refractory follicular lymphoma (R/R FL) receiving two or more lines of systemic therapy (3L+) from both the Italian hospital and societ...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
AboutScience Srl
2024-12-01
|
| Series: | Global & Regional Health Technology Assessment |
| Subjects: | |
| Online Access: | https://journals.aboutscience.eu/index.php/grhta/article/view/3170 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850103960468193280 |
|---|---|
| author | Marco Bellone Alice Sabinot Alessandro D’Arpino Emanuela Omodeo Salè Daniela Ghislieri Lorenzo Pradelli |
| author_facet | Marco Bellone Alice Sabinot Alessandro D’Arpino Emanuela Omodeo Salè Daniela Ghislieri Lorenzo Pradelli |
| author_sort | Marco Bellone |
| collection | DOAJ |
| description | Objective: A per-patient cost of therapy administration model was developed to estimate the cost of mosunetuzumab vs. tisagenlecleucel in patients with relapsing or refractory follicular lymphoma (R/R FL) receiving two or more lines of systemic therapy (3L+) from both the Italian hospital and societal perspectives.
Methods: A per-patient total cost of therapy administration model was developed to compare the resource consumption of two treatments – mosunetuzumab and tisagenlecleucel. The model considered direct costs such as healthcare labor costs for drug preparation and administration, non-drug consumable costs, and drug purchase. Indirect costs such as patient and caregiver’s loss of productivity, transportation, and relocation were also considered. The unit costs and resource use data were retrieved from literature and standard Italian tariffs. To appraise the impact of patients’ residency on access-to-care and out-of-pocket expenses, three scenario analyses were conducted.
Results: Over 1 year, mosunetuzumab costs approximately one-fourth of tisagenlecleucel per patient. The base-case scenario showed a hospital cost reduction of €158,870 per patient with mosunetuzumab, increasing to €161,974 when including societal costs. Scenario analyses for the societal perspective estimated cost differences of −€161,170, −€166,507, and −€166,811 for scenarios A, B, and C, respectively. Sensitivity analysis indicated that tisagenlecleucel’s price had the greatest impact on cost differences, followed by mosunetuzumab’s price.
Conclusions: This analysis identifies mosunetuzumab as an accessible therapeutic option for 3L+ R/R FL patients in Italy. Future research should collect real-time data and evaluate long-term outcomes.
|
| format | Article |
| id | doaj-art-5fd9bb72701a4cd59e5cbd1ed36469f8 |
| institution | DOAJ |
| issn | 2284-2403 2283-5733 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | AboutScience Srl |
| record_format | Article |
| series | Global & Regional Health Technology Assessment |
| spelling | doaj-art-5fd9bb72701a4cd59e5cbd1ed36469f82025-08-20T02:39:25ZengAboutScience SrlGlobal & Regional Health Technology Assessment2284-24032283-57332024-12-0111110.33393/grhta.2024.3170A 1-year per-patient cost of therapy administration analysis of mosunetuzumab and tisagenlecleucel in relapsed or refractory follicular lymphoma patients receiving two or more lines of systemic therapyMarco Bellone0Alice Sabinot1Alessandro D’Arpino2Emanuela Omodeo Salè3Daniela Ghislieri4Lorenzo Pradelli5Department of Health Economics and Outcomes Research, AdRes Health Economics & Outcomes Research, Turin - ItalyDepartment of Health Economics and Outcomes Research, AdRes Health Economics & Outcomes Research, Turin - ItalyPharmacy Unit, Santa Maria della Misericordia Hospital, Perugia - ItalyDivision of Pharmacy, IEO European Institute of Oncology IRCCS, Milan - ItalyMarket Access Department, Roche S.p.A., Monza - ItalyDepartment of Health Economics and Outcomes Research, AdRes Health Economics & Outcomes Research, Turin - ItalyObjective: A per-patient cost of therapy administration model was developed to estimate the cost of mosunetuzumab vs. tisagenlecleucel in patients with relapsing or refractory follicular lymphoma (R/R FL) receiving two or more lines of systemic therapy (3L+) from both the Italian hospital and societal perspectives. Methods: A per-patient total cost of therapy administration model was developed to compare the resource consumption of two treatments – mosunetuzumab and tisagenlecleucel. The model considered direct costs such as healthcare labor costs for drug preparation and administration, non-drug consumable costs, and drug purchase. Indirect costs such as patient and caregiver’s loss of productivity, transportation, and relocation were also considered. The unit costs and resource use data were retrieved from literature and standard Italian tariffs. To appraise the impact of patients’ residency on access-to-care and out-of-pocket expenses, three scenario analyses were conducted. Results: Over 1 year, mosunetuzumab costs approximately one-fourth of tisagenlecleucel per patient. The base-case scenario showed a hospital cost reduction of €158,870 per patient with mosunetuzumab, increasing to €161,974 when including societal costs. Scenario analyses for the societal perspective estimated cost differences of −€161,170, −€166,507, and −€166,811 for scenarios A, B, and C, respectively. Sensitivity analysis indicated that tisagenlecleucel’s price had the greatest impact on cost differences, followed by mosunetuzumab’s price. Conclusions: This analysis identifies mosunetuzumab as an accessible therapeutic option for 3L+ R/R FL patients in Italy. Future research should collect real-time data and evaluate long-term outcomes. https://journals.aboutscience.eu/index.php/grhta/article/view/3170Economic evaluationHealthcare costsMicro-costingOncology |
| spellingShingle | Marco Bellone Alice Sabinot Alessandro D’Arpino Emanuela Omodeo Salè Daniela Ghislieri Lorenzo Pradelli A 1-year per-patient cost of therapy administration analysis of mosunetuzumab and tisagenlecleucel in relapsed or refractory follicular lymphoma patients receiving two or more lines of systemic therapy Global & Regional Health Technology Assessment Economic evaluation Healthcare costs Micro-costing Oncology |
| title | A 1-year per-patient cost of therapy administration analysis of mosunetuzumab and tisagenlecleucel in relapsed or refractory follicular lymphoma patients receiving two or more lines of systemic therapy |
| title_full | A 1-year per-patient cost of therapy administration analysis of mosunetuzumab and tisagenlecleucel in relapsed or refractory follicular lymphoma patients receiving two or more lines of systemic therapy |
| title_fullStr | A 1-year per-patient cost of therapy administration analysis of mosunetuzumab and tisagenlecleucel in relapsed or refractory follicular lymphoma patients receiving two or more lines of systemic therapy |
| title_full_unstemmed | A 1-year per-patient cost of therapy administration analysis of mosunetuzumab and tisagenlecleucel in relapsed or refractory follicular lymphoma patients receiving two or more lines of systemic therapy |
| title_short | A 1-year per-patient cost of therapy administration analysis of mosunetuzumab and tisagenlecleucel in relapsed or refractory follicular lymphoma patients receiving two or more lines of systemic therapy |
| title_sort | 1 year per patient cost of therapy administration analysis of mosunetuzumab and tisagenlecleucel in relapsed or refractory follicular lymphoma patients receiving two or more lines of systemic therapy |
| topic | Economic evaluation Healthcare costs Micro-costing Oncology |
| url | https://journals.aboutscience.eu/index.php/grhta/article/view/3170 |
| work_keys_str_mv | AT marcobellone a1yearperpatientcostoftherapyadministrationanalysisofmosunetuzumabandtisagenlecleucelinrelapsedorrefractoryfollicularlymphomapatientsreceivingtwoormorelinesofsystemictherapy AT alicesabinot a1yearperpatientcostoftherapyadministrationanalysisofmosunetuzumabandtisagenlecleucelinrelapsedorrefractoryfollicularlymphomapatientsreceivingtwoormorelinesofsystemictherapy AT alessandrodarpino a1yearperpatientcostoftherapyadministrationanalysisofmosunetuzumabandtisagenlecleucelinrelapsedorrefractoryfollicularlymphomapatientsreceivingtwoormorelinesofsystemictherapy AT emanuelaomodeosale a1yearperpatientcostoftherapyadministrationanalysisofmosunetuzumabandtisagenlecleucelinrelapsedorrefractoryfollicularlymphomapatientsreceivingtwoormorelinesofsystemictherapy AT danielaghislieri a1yearperpatientcostoftherapyadministrationanalysisofmosunetuzumabandtisagenlecleucelinrelapsedorrefractoryfollicularlymphomapatientsreceivingtwoormorelinesofsystemictherapy AT lorenzopradelli a1yearperpatientcostoftherapyadministrationanalysisofmosunetuzumabandtisagenlecleucelinrelapsedorrefractoryfollicularlymphomapatientsreceivingtwoormorelinesofsystemictherapy AT marcobellone 1yearperpatientcostoftherapyadministrationanalysisofmosunetuzumabandtisagenlecleucelinrelapsedorrefractoryfollicularlymphomapatientsreceivingtwoormorelinesofsystemictherapy AT alicesabinot 1yearperpatientcostoftherapyadministrationanalysisofmosunetuzumabandtisagenlecleucelinrelapsedorrefractoryfollicularlymphomapatientsreceivingtwoormorelinesofsystemictherapy AT alessandrodarpino 1yearperpatientcostoftherapyadministrationanalysisofmosunetuzumabandtisagenlecleucelinrelapsedorrefractoryfollicularlymphomapatientsreceivingtwoormorelinesofsystemictherapy AT emanuelaomodeosale 1yearperpatientcostoftherapyadministrationanalysisofmosunetuzumabandtisagenlecleucelinrelapsedorrefractoryfollicularlymphomapatientsreceivingtwoormorelinesofsystemictherapy AT danielaghislieri 1yearperpatientcostoftherapyadministrationanalysisofmosunetuzumabandtisagenlecleucelinrelapsedorrefractoryfollicularlymphomapatientsreceivingtwoormorelinesofsystemictherapy AT lorenzopradelli 1yearperpatientcostoftherapyadministrationanalysisofmosunetuzumabandtisagenlecleucelinrelapsedorrefractoryfollicularlymphomapatientsreceivingtwoormorelinesofsystemictherapy |